Literature DB >> 10435115

A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA.

A Hombach1, D Koch, R Sircar, C Heuser, V Diehl, W Kruis, C Pohl, H Abken.   

Abstract

Chimeric T cell receptors with specificity for tumor-associated antigens are successfully used to target T cells to tumor cells. The efficacy of this approach, however, is reduced by soluble antigen that is frequently present in high serum concentrations. To overcome this situation, we constructed an anti-CEA chimeric receptor whose extracellular moiety is composed of a humanized single chain antibody fragment (scFv) derived from the anti-CEA mAb BW431/26 and the CH2/CH3 constant domains of human IgG. The intracellular moiety consists of the gamma-signaling chain of the human Fc epsilon RI receptor constituting a completely humanized chimeric receptor. After transfection, the humBW431/26 scFv-CH2CH3-gamma receptor is expressed as a homodimer on the surface of MD45 T cells. Co-incubation with CEA+ tumor cells specifically activates grafted MD45 T cells indicated by IL-2 secretion and cytolytic activity against CEA+ tumor cells. Notably, the efficacy of receptor-mediated activation is not affected by soluble CEA up to 25 micrograms/ml demonstrating the usefulness of this chimeric receptor for specific cellular activation by membrane-bound CEA even in the presence of high concentrations of CEA, as found in patients during progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435115     DOI: 10.1038/sj.gt.3300813

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  24 in total

1.  Eradication of melanomas by targeted elimination of a minor subset of tumor cells.

Authors:  Patrick Schmidt; Caroline Kopecky; Andreas Hombach; Paola Zigrino; Cornelia Mauch; Hinrich Abken
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 2.  Quantitative Imaging Approaches to Study the CAR Immunological Synapse.

Authors:  Malini Mukherjee; Emily M Mace; Alexandre F Carisey; Nabil Ahmed; Jordan S Orange
Journal:  Mol Ther       Date:  2017-06-26       Impact factor: 11.454

3.  A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.

Authors:  A Hombach; C Schlimper; E Sievers; S Frank; H H Schild; T Sauerbruch; I G H Schmidt-Wolf; H Abken
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

4.  T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor.

Authors:  Florian Full; Manfred Lehner; Veronika Thonn; Gabriel Goetz; Brigitte Scholz; Kerstin B Kaufmann; Michael Mach; Hinrich Abken; Wolfgang Holter; Armin Ensser
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

5.  Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.

Authors:  C O Yun; K F Nolan; E J Beecham; R A Reisfeld; R P Junghans
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

Review 6.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Authors:  Carlos A Ramos; Gianpietro Dotti
Journal:  Expert Opin Biol Ther       Date:  2011-04-04       Impact factor: 4.388

7.  Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

Authors:  Gregory A Rufener; Oliver W Press; Philip Olsen; Sang Yun Lee; Michael C Jensen; Ajay K Gopal; Barbara Pender; Lihua E Budde; Jeffrey K Rossow; Damian J Green; David G Maloney; Stanley R Riddell; Brian G Till
Journal:  Cancer Immunol Res       Date:  2016-04-21       Impact factor: 11.151

Review 8.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 9.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

Review 10.  Chimeric antigen receptor-redirected T cells return to the bench.

Authors:  Claudia Geldres; Barbara Savoldo; Gianpietro Dotti
Journal:  Semin Immunol       Date:  2016-01-12       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.